Recursion Pharmaceuticals Appoints New Chief Medical Officer with Extensive Oncology and Regulatory Experience

summarizeSummary

Recursion Pharmaceuticals appointed Dr. Vicki Goodman as its new Chief Medical Officer, bringing over two decades of experience in oncology drug development and regulatory affairs, as Dr. David Mauro transitions to an advisory role.

check_boxKey Events

• New Chief Medical Officer Appointed

  Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026.

• Outgoing CMO Transitions to Advisory Role

  David Mauro, M.D., Ph.D., will transition out of the CMO role but continue to serve in an advisory capacity until May 29, 2026.

• Extensive Clinical Development Expertise

  Dr. Goodman brings over two decades of experience in oncology drug development, including executive roles at Mural Oncology, Exelixis, Merck, and Bristol Myers Squibb, as well as experience as an FDA reviewer.

auto_awesomeAnalysis

Recursion Pharmaceuticals, a clinical-stage TechBio company, announced a significant leadership change with the appointment of Dr. Vicki Goodman as its new Chief Medical Officer. This is an important development for a company focused on advancing a pipeline of investigational medicines, as the CMO role is critical for guiding clinical development and regulatory strategy. Dr. Goodman's extensive background in oncology drug development, including executive roles at major pharmaceutical companies and experience as an FDA reviewer, brings valuable expertise, particularly in late-stage clinical development and navigating regulatory milestones. The transition of the outgoing CMO, Dr. David Mauro, to an advisory capacity suggests a managed and amicable change, minimizing potential disruption. This strategic hire is aimed at strengthening the company's ability to translate scientific insights into successful clinical programs.